JP2013040142A - Ornithine-containing composition - Google Patents
Ornithine-containing composition Download PDFInfo
- Publication number
- JP2013040142A JP2013040142A JP2011178937A JP2011178937A JP2013040142A JP 2013040142 A JP2013040142 A JP 2013040142A JP 2011178937 A JP2011178937 A JP 2011178937A JP 2011178937 A JP2011178937 A JP 2011178937A JP 2013040142 A JP2013040142 A JP 2013040142A
- Authority
- JP
- Japan
- Prior art keywords
- ornithine
- composition
- salt
- composition according
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 105
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 title claims abstract description 74
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 title claims abstract description 68
- 229960003104 ornithine Drugs 0.000 title claims abstract description 68
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 150000003839 salts Chemical class 0.000 claims abstract description 65
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 28
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000011701 zinc Substances 0.000 claims abstract description 22
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 22
- 208000004210 Pressure Ulcer Diseases 0.000 claims abstract description 18
- 235000016709 nutrition Nutrition 0.000 claims abstract description 18
- 235000013343 vitamin Nutrition 0.000 claims abstract description 14
- 230000006872 improvement Effects 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 230000035764 nutrition Effects 0.000 claims abstract description 9
- 238000011084 recovery Methods 0.000 claims abstract description 9
- 230000002980 postoperative effect Effects 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 32
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 26
- 235000013361 beverage Nutrition 0.000 claims description 16
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 15
- 229930003268 Vitamin C Natural products 0.000 claims description 15
- 235000019154 vitamin C Nutrition 0.000 claims description 15
- 239000011718 vitamin C Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 11
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 235000019155 vitamin A Nutrition 0.000 claims description 9
- 239000011719 vitamin A Substances 0.000 claims description 9
- 229940045997 vitamin a Drugs 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 235000013305 food Nutrition 0.000 description 18
- 230000000694 effects Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 9
- -1 inorganic acid salts Chemical class 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000006229 amino acid addition Effects 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 229940049920 malate Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Chemical class 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000014214 soft drink Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QHNVWXUULMZJKD-UHFFFAOYSA-N 3,4-didehydroretinal Chemical compound O=CC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C QHNVWXUULMZJKD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 2
- 229930195715 D-glutamine Natural products 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229930000083 3-dehydroretinol Natural products 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical class OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical class OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000020719 Satsuma Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- SYESMXTWOAQFET-YCNIQYBTSA-N all-trans-3,4-didehydroretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=CCC1(C)C SYESMXTWOAQFET-YCNIQYBTSA-N 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical class OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical class 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical class OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を含有する組成物に関する。 The present invention relates to a composition containing ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins.
褥瘡とは、体の接触面から受ける圧迫により組織の末梢血管が閉塞し、組織の壊死を引き起こす病態であり、その治癒には長期間を要する場合が多い。よって、長期間、寝具上に寝ている状態にある老人や長期療養患者は、褥瘡（いわゆる床擦れ）が生じやすく、看護上の大きな問題となっている。また、褥瘡は、ヒト以外の動物にも発症する疾病であり、例えばウマの鞍ずれも褥瘡のひとつである。 Pressure sores are pathological conditions that cause peripheral blood vessels in the tissue to be blocked by pressure received from the contact surface of the body and cause necrosis of the tissue, and healing often takes a long time. Therefore, elderly people who have been sleeping on bedding for a long time and long-term care patients are likely to develop pressure ulcers (so-called floor rubbing), which is a major nursing problem. Pressure ulcers are diseases that develop in animals other than humans. For example, horse sores are one type of pressure ulcer.
褥瘡の治療剤としては、ブロイメランを含む軟膏（非特許文献１）、ブクラデシンナトリウムを含む軟膏等が用いられているが（非特許文献２）、いずれも出血、疼痛等の副作用が知られており、より安全な褥瘡の治療が求められている。オルニチンには一定の褥瘡の治療効果が認められ（非特許文献３）、グルタミンにも一定の褥瘡の治療効果が認められている（非特許文献４）。 As therapeutic agents for pressure ulcers, an ointment containing bromelane (Non-patent Document 1), an ointment containing bucladecin sodium (Non-patent Document 2), and the like, both have known side effects such as bleeding and pain. There is a need for safer treatment of pressure ulcers. Ornithine has a certain pressure ulcer therapeutic effect (Non-patent Document 3), and glutamine has a certain pressure ulcer therapeutic effect (Non-patent Document 4).
しかしながら、単純にオルニチンとグルタミンとを配合するとタンパク質量（アミノ酸を含む）が増大し体に窒素負荷がかかることが懸念される。そのような状況下で、一定のタンパク質量の下で窒素負荷が低減できるように、タンパク質量におけるオルニチンの割合を最適化し、グルタミンなどとの相乗効果を発揮させようとしたものはなかった。 However, there is a concern that simply adding ornithine and glutamine increases the amount of protein (including amino acids) and places a nitrogen load on the body. Under such circumstances, there has been no attempt to optimize the ratio of ornithine in the amount of protein so as to reduce the nitrogen load under a certain amount of protein and to exert a synergistic effect with glutamine or the like.
本発明の目的は、オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を含有する組成物を提供することにある。 An object of the present invention is to provide a composition containing ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins.
本発明は、下記の（１）〜（１９）に関する。
（１）オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を含有する組成物。
（２）オルニチンまたはその塩が、オルニチンとして、組成物に含有されるタンパク質量の１０〜７０質量％であることを特徴とする（１）記載の組成物。
（３）オルニチンまたはその塩が、オルニチンとして、組成物全量の５〜４５質量％であることを特徴とする（１）または（２）記載の組成物。
（４）オルニチンまたはその塩がオルニチンとして８００〜１７００ｍｇ含まれることを特徴とする（１）から（３）のいずれかに記載の組成物。
（５）グルタミンまたはその塩がグルタミンとして１００〜２０００ｍｇ含まれることを特徴とする（１）から（４）のいずれかに記載の組成物。
（６）オルニチンまたはその塩とグルタミンまたはその塩との重量組成比がオルニチンおよびグルタミンとして１：４〜９：４である（１）から（５）のいずれかに記載の組成物。
（７）亜鉛が０．１〜１５ｍｇ含まれることを特徴とする（１）から（６）のいずれかに記載の組成物。
（８）オルニチンまたはその塩と亜鉛との重量組成比がオルニチンおよび亜鉛として７０：３〜１０：１である（１）から（７）のいずれかに記載の組成物。
（９）ビタミン類がビタミンＡおよびビタミンＣからなる群から選ばれる１以上のビタミン類を含有する（１）から（８）のいずれかに記載の組成物。
（１０）ビタミンＡが１０〜６００μｇ含まれることを特徴とする（９）記載の組成物。
（１１）ビタミンＣが２４〜５００ｍｇ含まれることを特徴とする（９）記載の組成物。
（１２）オルニチンまたはその塩とビタミンＣとの重量組成比がオルニチンとビタミンＣとして３：２〜７：２である（９）または（１１）記載の組成物。
（１３）組成物が粉末または顆粒であることを特徴とする（１）から（１２）のいずれかに記載の組成物。
（１４）酸味料を含有させる工程を含むオルニチンまたはその塩、グルタミンまたはその塩、亜鉛、ビタミン類を含有する組成物の製造方法。
（１５）オルニチンまたはその塩が、組成物に含有されるタンパク質量の１０〜７０質量％であることを特徴とする（１４）記載の製造方法。
（１６）酸味料がクエン酸である（１４）または（１５）記載の製造方法。
（１７）（１）から（１３）のいずれかに記載の組成物を含有、混合、溶解させた５０〜２４０ｍｌの飲料。
（１８）ｐＨが３．０〜４．０であることを特徴とする（１７）記載の飲料。
（１９）（１）から（１３）のいずれかに記載の組成物を有効成分とする栄養改善用組成物。
（２０）栄養改善が褥瘡の予防、または改善、術後回復に関する栄養改善である（１９）記載の栄養改善用組成物。
（２１）（１）から（１３）のいずれかに記載の組成物を有効成分とする褥瘡の予防剤、抑制剤、改善剤、または術後回復剤。
The present invention relates to the following (1) to (19).
(1) A composition containing ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins.
(2) The composition according to (1), wherein ornithine or a salt thereof is 10 to 70% by mass of ornithine in the amount of protein contained in the composition.
(3) The composition according to (1) or (2), wherein ornithine or a salt thereof is ornithine in an amount of 5 to 45% by mass based on the total amount of the composition.
(4) The composition according to any one of (1) to (3), wherein ornithine or a salt thereof is contained in an amount of 800 to 1700 mg as ornithine.
(5) The composition according to any one of (1) to (4), wherein glutamine or a salt thereof is contained in an amount of 100 to 2000 mg as glutamine.
(6) The composition according to any one of (1) to (5), wherein the weight composition ratio of ornithine or a salt thereof and glutamine or a salt thereof is 1: 4 to 9: 4 as ornithine and glutamine.
(7) The composition according to any one of (1) to (6), wherein 0.1 to 15 mg of zinc is contained.
(8) The composition according to any one of (1) to (7), wherein the weight composition ratio of ornithine or a salt thereof and zinc is 70: 3 to 10: 1 as ornithine and zinc.
(9) The composition according to any one of (1) to (8), wherein the vitamin contains one or more vitamins selected from the group consisting of vitamin A and vitamin C.
(10) The composition according to (9), wherein 10 to 600 μg of vitamin A is contained.
(11) The composition according to (9), comprising 24 to 500 mg of vitamin C.
(12) The composition according to (9) or (11), wherein the weight composition ratio of ornithine or a salt thereof and vitamin C is 3: 2 to 7: 2 as ornithine and vitamin C.
(13) The composition according to any one of (1) to (12), wherein the composition is a powder or a granule.
(14) A method for producing a composition containing ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins, comprising a step of containing a sour agent.
(15) The production method according to (14), wherein ornithine or a salt thereof is 10 to 70% by mass of the amount of protein contained in the composition.
(16) The production method according to (14) or (15), wherein the acidulant is citric acid.
(17) A 50 to 240 ml beverage containing, mixed and dissolved the composition according to any one of (1) to (13).
(18) The beverage according to (17), which has a pH of 3.0 to 4.0.
(19) A nutrition improving composition comprising the composition according to any one of (1) to (13) as an active ingredient.
(20) The nutrition improving composition according to (19), wherein the nutritional improvement is nutritional improvement related to prevention or improvement of pressure ulcer and recovery after surgery.
(21) A pressure ulcer preventive agent, inhibitor, ameliorating agent, or postoperative recovery agent comprising the composition according to any one of (1) to (13) as an active ingredient.
本発明により、オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を含有する組成物を提供することができる。該組成物は、褥瘡の予防、抑制、改善、術後回復等として用いることができる。 According to the present invention, a composition containing ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins can be provided. The composition can be used for prevention, suppression, improvement, postoperative recovery, etc. of pressure ulcers.
本発明で用いられるオルニチンとしては、Ｌ−オルニチンまたはＤ−オルニチンがあげられるが、Ｌ−オルニチンが好ましい。本発明で用いられるオルニチンは、どのような製造法によって得られたものであってもよく、Ｌ−オルニチンの製造法としては、例えば化学合成法［Ｃｏｌｌ．Ｃｚｅｃｈｏｓｌｏｖ．Ｃｈｅｍ．Ｃｏｍｍｕｎ．，２４，１９９３（１９５９） ］、発酵法（特開昭５３−２４０９６号公報、特開昭６１−１１９１９４号公報）等の方法があげられる。 Examples of ornithine used in the present invention include L-ornithine and D-ornithine, with L-ornithine being preferred. Ornithine used in the present invention may be obtained by any production method. Examples of the production method of L-ornithine include chemical synthesis [Col. Czechoslov. Chem. Commun. , 24, 1993 (1959)], fermentation methods (Japanese Patent Laid-Open Nos. 53-24096 and 61-119194), and the like.
また、Ｌ−オルニチンおよびＤ−オルニチンは、シグマ−アルドリッチ社等より購入することもできる。オルニチンの塩としては、例えば酸付加塩、金属塩、アンモニウム塩、有機アミン付加塩、アミノ酸付加塩等があげられる。酸付加塩としては、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩、酢酸塩、マレイン酸塩、フマル酸塩、クエン酸塩、リンゴ酸塩、乳酸塩、α−ケトグルタル酸塩、グルコン酸塩、カプリル酸塩等の有機酸塩があげられる。 L-ornithine and D-ornithine can also be purchased from Sigma-Aldrich. Examples of ornithine salts include acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts, and the like. Acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, acetate, maleate, fumarate, citrate, malate, lactate, α-ketoglutarate And organic acid salts such as gluconate and caprylate.
金属塩としては、ナトリウム塩、カリウム塩等のアルカリ金属塩、マグネシウム塩、カルシウム塩等のアルカリ土類金属塩、アルミニウム塩、亜鉛塩等があげられる。アンモニウム塩としては、アンモニウム、テトラメチルアンモニウム等の塩があげられる。有機アミン付加塩としては、モルホリン、ピペリジン等の塩があげられる。アミノ酸付加塩としては、グリシン、フェニルアラニン、リジン、アスパラギン酸、グルタミン酸等の塩があげられる。上記のオルニチンの塩のうち、塩酸塩、クエン酸塩、リンゴ酸塩、α−ケトグルタル酸塩、アスパラギン酸塩が好ましく用いられるが、他の塩、または２以上の塩を適宜組み合わせて用いてもよい。 Examples of the metal salt include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt and zinc salt. Examples of ammonium salts include salts such as ammonium and tetramethylammonium. Examples of the organic amine addition salt include salts of morpholine, piperidine and the like. Examples of amino acid addition salts include salts of glycine, phenylalanine, lysine, aspartic acid, glutamic acid and the like. Of the above ornithine salts, hydrochloride, citrate, malate, α-ketoglutarate and aspartate are preferably used, but other salts or two or more salts may be used in appropriate combination. Good.
本発明の組成物中のオルニチンまたはその塩の配合量は、適宜選択されるが、オルニチンとして、組成物に含有されるタンパク質量（アミノ酸も含む。）に対して通常は１０〜７０質量％、好ましくは２０〜６０質量％、特に好ましくは３０〜５０質量％である。１０％未満の場合はオルニチンに由来する効果が生じにくくなる可能性があり、７０％より多い場合はその他のアミノ酸との相乗効果が生じにくくなる可能性がある。 The compounding amount of ornithine or a salt thereof in the composition of the present invention is appropriately selected, but usually 10 to 70% by mass with respect to the amount of protein (including amino acids) contained in the composition as ornithine, Preferably it is 20-60 mass%, Most preferably, it is 30-50 mass%. If it is less than 10%, the effect derived from ornithine may be difficult to occur, and if it is more than 70%, a synergistic effect with other amino acids may be difficult to occur.
本発明の組成物中のオルニチンまたはその塩の配合量は、適宜選択されるが、オルニチンとして、組成物全量に対して通常は５〜４５質量％、好ましくは１５〜３５質量％、特に好ましくは２０〜３０質量％である。５％未満の場合はオルニチンに由来する効果が生じにくくなる可能性があり、４５％より多い場合はその他のアミノ酸と合計した組成物全量に対するタンパク質の割合が高くなり、体に与える窒素負荷の観点から好ましくない可能性がある。 The blending amount of ornithine or a salt thereof in the composition of the present invention is appropriately selected. As ornithine, it is usually 5 to 45% by mass, preferably 15 to 35% by mass, particularly preferably based on the total amount of the composition. It is 20-30 mass%. If it is less than 5%, the effect derived from ornithine may be less likely to occur, and if it is more than 45%, the ratio of the protein to the total amount of the composition totaled with other amino acids becomes high, and the viewpoint of the nitrogen load given to the body May be undesirable.
本発明の組成物中のオルニチンまたはその塩の配合量は、適宜選択されるが、オルニチンとして、通常は８００〜１７００ｍｇ、好ましくは１０００〜１５００ｍｇ、特に好ましくは１２００〜１３００ｍｇである。８００ｍｇ未満の場合はオルニチンに由来する効果が生じにくくなる可能性があり、１７００ｍｇより多い場合はその他のアミノ酸と合計した組成物中のタンパク質量が高くなり、体に与える窒素負荷の観点から好ましくない可能性がある。 The blending amount of ornithine or a salt thereof in the composition of the present invention is appropriately selected, and as ornithine, it is usually 800 to 1700 mg, preferably 1000 to 1500 mg, particularly preferably 1200 to 1300 mg. If it is less than 800 mg, the effect derived from ornithine may be less likely to occur, and if it is more than 1700 mg, the amount of protein in the composition combined with other amino acids becomes high, which is not preferable from the viewpoint of nitrogen load on the body. there is a possibility.
本発明で用いられるグルタミンとしては、Ｌ−グルタミンまたはＤ−グルタミンがあげられるが、Ｌ−グルタミンが好ましい。本発明で用いられるグルタミンは、どのような製造法によって得られたものであってもよく、Ｌ−グルタミンの製造法としては、例えばＷＯ２００７／０７４８５７等の方法があげられる。 Examples of glutamine used in the present invention include L-glutamine and D-glutamine, with L-glutamine being preferred. The glutamine used in the present invention may be obtained by any production method, and examples of the production method of L-glutamine include methods such as WO2007 / 074857.
また、Ｌ−グルタミンおよびＤ−グルタミンは、シグマ−アルドリッチ社等より購入することもできる。グルタミンの塩としては、例えば酸付加塩、金属塩、アンモニウム塩、有機アミン付加塩、アミノ酸付加塩等があげられる。酸付加塩としては、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩、酢酸塩、マレイン酸塩、フマル酸塩、クエン酸塩、リンゴ酸塩、乳酸塩、α−ケトグルタル酸塩、グルコン酸塩、カプリル酸塩等の有機酸塩があげられる。 L-glutamine and D-glutamine can also be purchased from Sigma-Aldrich. Examples of glutamine salts include acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts, and the like. Acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, acetate, maleate, fumarate, citrate, malate, lactate, α-ketoglutarate And organic acid salts such as gluconate and caprylate.
本発明の組成物中のグルタミンまたはその塩の配合量は、適宜選択されるが、グルタミンとして、通常は１００〜２０００ｍｇ、好ましくは５００〜１６００ｍｇ、特に好ましくは９００〜１２００ｍｇである。１００ｍｇ未満の場合はグルタミンに由来する効果が生じにくくなる可能性があり、２０００ｍｇより多い場合はその他のアミノ酸と合計した組成物中のタンパク質量が高くなり体に与える窒素負荷の観点から好ましくない可能性がある。 The compounding amount of glutamine or a salt thereof in the composition of the present invention is appropriately selected, but is usually 100 to 2000 mg, preferably 500 to 1600 mg, particularly preferably 900 to 1200 mg as glutamine. If the amount is less than 100 mg, the effect derived from glutamine may be less likely to occur, and if it is more than 2000 mg, the amount of protein in the composition combined with other amino acids may increase, which may be undesirable from the viewpoint of nitrogen load on the body. There is sex.
本発明の組成物中のオルニチンまたはその塩とグルタミンまたはその塩との重量組成比がオルニチンおよびグルタミンとして、特に限定はないが、１：４〜９：４が好ましく、３：４〜７：４がさらに好ましく、５：４が特に好ましい。１：４〜９：４の組成比を外れると、オルニチンまたはグルタミンの一方に由来する効果が強くなるため相乗効果を生じにくくなる可能性があり、３：４〜７：４の組成比において相乗効果を得られやすく、５：４に近い組成比においてさらに相乗効果を得られやすい。 The weight composition ratio of ornithine or a salt thereof and glutamine or a salt thereof in the composition of the present invention is not particularly limited as ornithine and glutamine, but is preferably 1: 4 to 9: 4, and 3: 4 to 7: 4. Is more preferable, and 5: 4 is particularly preferable. If the composition ratio is outside the range of 1: 4 to 9: 4, the effect derived from either ornithine or glutamine becomes strong, and thus there is a possibility that a synergistic effect is difficult to occur, and there is a synergy in the composition ratio of 3: 4 to 7: 4. It is easy to obtain an effect, and a synergistic effect is further easily obtained at a composition ratio close to 5: 4.
本発明で用いられる亜鉛としては、組成物に亜鉛イオンを供給することができる可食性のものであれば、特に限定はないが、亜鉛を含有する塩や、亜鉛を高含有する酵母等の微生物を挙げることができる。特に好ましい亜鉛イオン添加物としては、グルコン酸亜鉛を挙げることができる。 The zinc used in the present invention is not particularly limited as long as it is edible so that zinc ions can be supplied to the composition. However, a salt containing zinc or a microorganism such as yeast containing a high amount of zinc. Can be mentioned. Particularly preferable zinc ion additives include zinc gluconate.
本発明の組成物中の亜鉛の配合量は、適宜選択されるが、通常は０．１〜１５ｍｇ、好ましくは３．０〜１２．０ｍｇ、特に好ましくは６．０〜９．０ｍｇである。０．１ｍｇ未満の場合は亜鉛に由来する創傷治癒効果が生じにくくなる可能性があり、１５ｍｇより多い場合は栄養機能食品の規格基準である１日当たりの摂取目安量に含まれる栄養成分量を超えることになる。 Although the compounding quantity of zinc in the composition of this invention is selected suitably, it is 0.1-15 mg normally, Preferably it is 3.0-12.0 mg, Most preferably, it is 6.0-9.0 mg. If it is less than 0.1 mg, there is a possibility that the wound healing effect derived from zinc is less likely to occur, and if it is more than 15 mg, it exceeds the amount of nutrients contained in the daily intake standard amount that is the standard for nutritional functional foods It will be.
本発明の組成物中のオルニチンまたはその塩と亜鉛との重量組成比がオルニチンおよび亜鉛として、特に限定はないが、７０：３〜１０：１が好ましく、２０：１〜４０：３がさらに好ましく、５０：３が特に好ましい。 The weight ratio of ornithine or a salt thereof and zinc in the composition of the present invention is not particularly limited as ornithine and zinc, but is preferably 70: 3 to 10: 1, more preferably 20: 1 to 40: 3. 50: 3 is particularly preferred.
本発明で用いられるビタミン類としては、例えばコエンザイムＱ１０、ビタミンＡ、ビタミンＢ１、ビタミンＢ２、ビタミンＢ６、ビタミンＢ１２、ビタミンＣ、ビタミンE等があげられるが、特にビタミンＡやビタミンＣが好ましい。ビタミンＡとしては、レチノール（ビタミンＡ１）、３−デヒドロレチノール（ビタミンＡ２）、レチナール、３−デヒドロレチナール、レチノイン酸、３−デヒドロレチノイン酸、これらの酢酸エステル、パルミチン酸エステル等の誘導体をあげることができる。ビタミンＣとしては、例えば、Ｌ−アスコルビン酸、Ｌ−アスコルビン酸ナトリウム、Ｌ−アスコルビン酸ステアリン酸エステル等をあげることができる。 Examples of vitamins used in the present invention include coenzyme Q10, vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin E and the like, and vitamin A and vitamin C are particularly preferable. Examples of vitamin A include retinol (vitamin A1), 3-dehydroretinol (vitamin A2), retinal, 3-dehydroretinal, retinoic acid, 3-dehydroretinoic acid, their acetates, and palmitic acid derivatives. Can do. Examples of vitamin C include L-ascorbic acid, sodium L-ascorbate, and L-ascorbic acid stearate.
本発明の組成物中のビタミンＡの配合量は、適宜選択されるが、通常は１０〜６００μｇ（６００μｇは２０００ＩＵ相当）、好ましくは１００〜４００μｇ、特に好ましくは１３５〜２００μｇである。１０μｇ未満の場合はビタミンＡに由来するコラーゲン合成や上皮生成の効果が生じにくくなる可能性があり、１３５μｇ未満の場合は栄養機能食品の規格基準である１日当たりの摂取目安量に含まれる栄養成分量４５０ＩＵを下回り、６００μｇより多い場合は栄養機能食品の規格基準である１日当たりの摂取目安量に含まれる栄養成分量２０００ＩＵを超えることになる。 The blending amount of vitamin A in the composition of the present invention is appropriately selected, but is usually 10 to 600 μg (600 μg is equivalent to 2000 IU), preferably 100 to 400 μg, particularly preferably 135 to 200 μg. If it is less than 10 μg, the effects of collagen synthesis and epithelial generation derived from vitamin A may be less likely to occur. If it is less than 135 μg, the nutritional components contained in the daily intake standard amount that is the standard for nutritional functional foods If the amount is less than 450 IU and more than 600 μg, it will exceed the amount of nutrient component 2000 IU included in the daily intake standard amount that is the standard for nutritional functional foods.
本発明の組成物中のビタミンＣとして通常は２４〜１０００ｍｇ、好ましくは１００〜７５０ｍｇ、特に好ましくは１５０〜５００ｍｇである。２４ｍｇ未満の場合は栄養機能食品の規格基準である１日当たりの摂取目安量に含まれる栄養成分量を下回りビタミンＣに由来する効果が生じにくくなる可能性があり、１００ｍｇで厚生労働省が定める１日当たりの栄養所要量所要量を満たす。１５０〜５００ｍｇは褥瘡発生時の１日の必要量として適当である。１０００ｍｇより多い場合は栄養機能食品の規格基準である１日当たりの摂取目安量に含まれる栄養成分量を超えることになる。 Vitamin C in the composition of the present invention is usually 24 to 1000 mg, preferably 100 to 750 mg, particularly preferably 150 to 500 mg. If it is less than 24 mg, it may be less than the amount of nutrients contained in the daily intake standard amount, which is the standard for functional nutritional foods, and it may be difficult to produce an effect derived from vitamin C. Meet nutritional requirements. 150 to 500 mg is appropriate as a necessary daily amount at the time of pressure ulcer development. When it is more than 1000 mg, it exceeds the amount of nutrient components contained in the daily intake standard amount that is the standard for functional nutritional foods.
本発明の組成物中のオルニチンまたはその塩とビタミンＣとの重量組成比がオルニチンおよびビタミンＣとして、特に限定はないが、３：２〜７：２が好ましく、２：１〜３：１がさらに好ましく、５：２が特に好ましい。 The weight composition ratio of ornithine or a salt thereof and vitamin C in the composition of the present invention is not particularly limited as ornithine and vitamin C, but is preferably 3: 2 to 7: 2, preferably 2: 1 to 3: 1. More preferred is 5: 2.
本発明の組成物は、例えば医薬、食品、飼料、食品添加物または飼料添加物として用いることができる。 The composition of the present invention can be used, for example, as a medicine, food, feed, food additive or feed additive.
また、本発明の組成物は、例えば粉末、顆粒、ペレット、錠剤、各種液剤の形態に加工、製造される。特に限定はないが、粉末や顆粒が好ましい。粉末または顆粒は、所望により糖類、甘味剤、酸味料、結合剤、抗酸化剤、着色剤、香料等を含有していてもよい。
糖類としては、食品等に使用できるものであれば特に制限されないが、例えば単糖類、二糖類、糖アルコール、オリゴ糖等があげられ、好ましくは二糖類、糖アルコールがあげられる。
Moreover, the composition of this invention is processed and manufactured in the form of a powder, a granule, a pellet, a tablet, and various liquid agents, for example. Although there is no limitation in particular, a powder and a granule are preferable. The powder or granule may contain saccharides, sweeteners, acidulants, binders, antioxidants, colorants, flavors and the like as desired.
The saccharide is not particularly limited as long as it can be used in foods and the like, and examples thereof include monosaccharides, disaccharides, sugar alcohols, oligosaccharides, and preferably disaccharides and sugar alcohols.
甘味剤としては、食品等に使用できるものであれば特に制限されないが、例えば、サッカリンナトリウム、グリチルリチン二カリウム、アスパルテーム、ステビア、ソーマチン等があげられる。本発明の粉末または顆粒中で甘味剤が占める割合は、一般的な使用の量の範囲内であれば特に限定されない。 The sweetening agent is not particularly limited as long as it can be used in foods, and examples thereof include sodium saccharin, dipotassium glycyrrhizin, aspartame, stevia, thaumatin and the like. The ratio of the sweetener in the powder or granule of the present invention is not particularly limited as long as it is within the range of general use.
酸味料としては、食品等に使用できるものであれば特に制限されないが、例えば、クエン酸、リン酸、リンゴ酸、酒石酸等があげられ、特にはクエン酸が好ましい。本発明の粉末または顆粒中で酸味料が占める割合は、一般的な使用の量の範囲内であれば特に限定されないが、通常は２〜１６重量％、好ましくは４〜１２重量％、特に好ましくは６〜１０重量％である。 The acidulant is not particularly limited as long as it can be used for foods and the like, and examples thereof include citric acid, phosphoric acid, malic acid, tartaric acid, and citric acid is particularly preferable. The proportion of the acidulant in the powder or granule of the present invention is not particularly limited as long as it is within the range of general use, but is usually 2 to 16% by weight, preferably 4 to 12% by weight, particularly preferably. Is 6 to 10% by weight.
結合剤としては、食品等に使用できるものであれば特に制限されないが、例えば、ゼラチン、プルラン等があげられる。本発明の造粒粉末もしくは顆粒または錠剤中で結合剤が占める割合は、一般的な使用の量の範囲内であれば特に限定されない。 The binder is not particularly limited as long as it can be used for foods and the like, and examples thereof include gelatin and pullulan. The proportion of the binder in the granulated powder or granule or tablet of the present invention is not particularly limited as long as it is within the range of general use.
また、本発明の組成物は、例えば食品添加剤として用いることができる。本発明の食品添加剤として飲食品に含有、混合、溶解させることができる。本発明の組成物を含有、混合、溶解した飲食品は、一般的な飲食品の製造方法を用いることにより、加工、製造することができる。例えば水、ジュース類、清涼飲料水、茶類、乳酸菌飲料、発酵乳、冷菓、バター、チーズ、ヨーグルト、加工乳、脱脂乳等の乳製品、ハム、ソーセージ、ハンバーグ等の畜肉製品、蒲鉾、竹輪、さつま揚げ等の魚肉練り製品、だし巻き、卵豆腐等の卵製品、クッキー、ゼリー、チューインガム、キャンディー、スナック菓子等の菓子類、パン類、麺類、漬物類、燻製品、干物、佃煮、塩蔵品、スープ類、調味料等、いずれの形態のものであってもよい。特に限定はないが、水、ジュース類、清涼飲料水、茶類、乳酸菌飲料、発酵乳、加工乳などの飲料が好ましい。 Moreover, the composition of this invention can be used, for example as a food additive. It can be contained, mixed and dissolved in food and drink as the food additive of the present invention. The food / beverage products containing, mixed and dissolved the composition of the present invention can be processed and manufactured by using a general method for manufacturing food / beverage products. For example, water, juices, soft drinks, teas, lactic acid bacteria beverages, fermented milk, frozen desserts, butter, cheese, yogurt, processed milk, skim milk and other dairy products, ham, sausage, hamburger and other meat products, rice cakes, bamboo rings , Fish products such as fried satsuma, egg products such as sushi rolls, egg tofu, cookies, jelly, chewing gum, candy, snacks It may be in any form, such as flavors or seasonings. Although there is no particular limitation, beverages such as water, juices, soft drinks, teas, lactic acid bacteria beverages, fermented milk and processed milk are preferred.
本発明の組成物を食品添加剤として含有、混合、溶解させた飲料のｐＨとしては、特に限定されないが、ｐＨ２．０〜８．０、好ましくはｐＨ２．５〜６．０、特に好ましくはｐＨ３．０〜４．０である。必要に応じて、有機酸、無機酸等のｐＨ調整剤で飲料のｐＨ調整を行うことができる。有機酸および無機酸としては、飲料の製造に用いられるものであれば特に制限されない。 The pH of the beverage containing, mixing and dissolving the composition of the present invention as a food additive is not particularly limited, but is pH 2.0 to 8.0, preferably pH 2.5 to 6.0, particularly preferably pH 3. 0.0 to 4.0. If necessary, the pH of the beverage can be adjusted with a pH adjuster such as an organic acid or an inorganic acid. The organic acid and the inorganic acid are not particularly limited as long as they are used for beverage production.
本発明の組成物を食品添加剤として含有、混合、溶解させた飲料の量としては、特に限定されないが、１０〜５００ｍｌ、好ましくは５０〜２４０ｍｌ、特に好ましくは８０〜１２０ｍｌである。１０ｍｌ未満の場合は組成物を含有、混合、溶解させにくくなる可能性があり、５０ｍｌ以上は少量の水分で摂取することができ、８０〜１２０ｍｌでは適度な水分摂取とともに味も良好に摂取できる。５００ｍｌより多い場合は水分が多くなり摂取が難しくなる。 The amount of the beverage containing, mixing and dissolving the composition of the present invention as a food additive is not particularly limited, but is 10 to 500 ml, preferably 50 to 240 ml, and particularly preferably 80 to 120 ml. If it is less than 10 ml, it may be difficult to contain, mix and dissolve the composition, 50 ml or more can be ingested with a small amount of water, and 80 to 120 ml can be ingested with moderate water intake and good taste. If it is more than 500 ml, the amount of water increases and it becomes difficult to take.
本発明の組成物は、そのまま例えば粉末食品、シート状食品、瓶詰め食品、缶詰食品、レトルト食品、カプセル食品、タブレット状食品、流動食品、ドリンク剤等の形態のものであってもよく、健康食品、機能性食品、栄養補助食品、特定保健用食品等の組成物としても用いることができる。 The composition of the present invention may be in the form of, for example, powdered food, sheet-like food, bottled food, canned food, retort food, capsule food, tablet food, liquid food, drink, etc. It can also be used as a composition for functional foods, dietary supplements, foods for specified health use, and the like.
本発明の組成物は、適宜選択されるが、組成物全量として通常は２．０ｇ〜８．０ｇ、好ましくは３．０〜７．０ｇ、特に好ましくは４．０〜６．０ｇである。２．０ｇ未満の場合は組成物中の有効成分が少量になるため効果が生じにくくなる可能性があり、８．０ｇより多い場合は組成物を適当な量の飲料などに含有、混合、溶解させにくくなる可能性がある。 The composition of the present invention is appropriately selected, but the total amount of the composition is usually 2.0 g to 8.0 g, preferably 3.0 to 7.0 g, particularly preferably 4.0 to 6.0 g. If the amount is less than 2.0 g, the amount of active ingredients in the composition may be small, so that the effect may be difficult to occur. If the amount is more than 8.0 g, the composition is contained, mixed, and dissolved in an appropriate amount of beverage. There is a possibility that it will be difficult to prevent.
本発明において栄養改善とは、例えば、褥瘡の予防または改善、術後回復があげられる。 In the present invention, nutritional improvement includes, for example, prevention or improvement of pressure ulcer and recovery after surgery.
本発明の組成物の摂取は、摂取形態、摂取者の年齢、体重等に応じて異なるが、通常成人一日あたり、一日一回ないし二回程度摂取する。摂取期間は特に限定はないが、通常は１日間〜１年間、好ましくは１週間〜３ヶ月間である。 Although the intake of the composition of the present invention varies depending on the intake form, the age, weight, etc. of the intake person, it is usually taken once or twice a day per day for an adult. The intake period is not particularly limited, but is usually 1 day to 1 year, preferably 1 week to 3 months.
組成物の投与形態は、治療に際し最も効果的なものを使用するのが望ましく、経口投与または、例えば静脈内、腹膜内もしくは皮下投与等の非経口投与をあげることができるが、経口投与が好ましい。 It is desirable to use the most effective form of the composition for the treatment, and oral administration or parenteral administration such as intravenous, intraperitoneal or subcutaneous administration is preferable, but oral administration is preferable. .
投与する剤形としては、例えば錠剤、散剤、顆粒剤、丸剤、懸濁剤、乳剤、浸剤・煎剤、カプセル剤、シロップ剤、液剤、エリキシル剤、エキス剤、チンキ剤、流エキス剤等の経口組成物、注射剤、点滴剤、クリーム剤、坐剤等の非経口組成物のいずれでもよいが、経口組成物として好適に用いられる。 Examples of dosage forms to be administered include tablets, powders, granules, pills, suspensions, emulsions, soaking and decoction, capsules, syrups, solutions, elixirs, extracts, tinctures, fluid extracts, etc. Any of parenteral compositions such as oral compositions, injections, drops, creams, suppositories and the like may be used, but they are preferably used as oral compositions.
また、本は発明の組成物は、例えば当該組成物を有効成分とする褥瘡の予防剤、抑制剤、改善剤、または術後回復剤として用いることができる。褥瘡の予防剤、抑制剤、改善剤、または術後回復剤については上述した配合、投与形態、剤形などを用いることができる。 In addition, the composition of the present invention can be used as, for example, a pressure ulcer preventive agent, inhibitor, ameliorating agent, or postoperative recovery agent comprising the composition as an active ingredient. As the pressure ulcer preventive, suppressant, ameliorating agent, or postoperative recovery agent, the above-mentioned combination, administration form, dosage form and the like can be used.
以下に、本発明の実施例を示す。 Examples of the present invention are shown below.
（オルニチン含有粉末の製造）
表１記載の処方で常法により粉末を製造した。成分の配合はＡ群とＢ群は同時に混合を行い、その後Ｃ群の成分を配合した。Ａ群とＢ群を同時に混合を行うことにより、飲料などへの溶解性が良い粉末が得られることが分かった。
Powders were produced in the usual manner according to the formulation shown in Table 1. The ingredients were mixed in the groups A and B at the same time, and then the ingredients in the group C were blended. It was found that a powder having good solubility in beverages and the like can be obtained by simultaneously mixing the A group and the B group.
（オルニチン含有飲料の製造）
実施例１で得た粉末５ｇを１０、５０、８０、１００、１２０、２４０、５００ｍｌの飲料水に配合し、それぞれについて溶解性および味の評価を行った。
(Manufacture of ornithine-containing beverages)
5 g of the powder obtained in Example 1 was blended in 10, 50, 80, 100, 120, 240, and 500 ml of drinking water, and the solubility and taste of each were evaluated.
溶解性の評価は、１：溶解せず沈殿が生じる、２：ある程度溶解しているが、若干溶け残りがある、３：溶解しており、特に問題にならない、４：溶解している。５：極めて良好に溶解している、の５段階で評価した。 The evaluation of the solubility is as follows: 1: dissolution does not occur, precipitation occurs, 2: dissolution occurs to some extent, but there is a little undissolved, 3: dissolution does not cause any problem, 4: dissolution occurs. 5: Evaluated in 5 grades: very good dissolution.
味の評価は、１：極めて良くない、２：良くない、３：普通であり、特に問題でない、４：良好である。５：極めて良好である、の５段階で評価した。
表２に示すように、１０ｍｌ未満の場合は組成物を溶解させにくくなり、５０ｍｌ以上は問題なく溶解した。また、味の観点からは８０〜２４０ｍｌにおいて良好に摂取できた。 As shown in Table 2, when the amount was less than 10 ml, it was difficult to dissolve the composition, and 50 ml or more was dissolved without any problem. Moreover, it was able to ingest well in 80-240 ml from a viewpoint of taste.
（オルニチン含有清涼飲料の製造）
実施例１で得た粉末５ｇを１００ｍｌのスポーツドリンク、紅茶（ストレートティー）に配合した。それぞれについて、溶解性・味は良好であり（実施例２と同様の評価で、スポーツドリンクは溶解性３、味３、紅茶は溶解性３、味３、であった。）、特に問題なく清涼飲料水に配合して摂取することができた。
(Manufacture of ornithine-containing soft drinks)
5 g of the powder obtained in Example 1 was blended with 100 ml of sports drink and black tea (straight tea). About each, solubility and taste are favorable (As the same evaluation as Example 2, sports drink was solubility 3, taste 3, and black tea was solubility 3, taste 3.) It was possible to mix and drink with drinking water.
本発明により、褥瘡の予防、抑制、改善や術後回復等の栄養改善に有用な、オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を含有する組成物を提供することができる。 According to the present invention, it is possible to provide a composition containing ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins, which is useful for improving nutrition such as prevention, suppression, improvement and postoperative recovery of pressure ulcers.
Claims (20)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011178937A JP5997425B2 (en) | 2011-08-18 | 2011-08-18 | Ornithine-containing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011178937A JP5997425B2 (en) | 2011-08-18 | 2011-08-18 | Ornithine-containing composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013040142A true JP2013040142A (en) | 2013-02-28 |
| JP2013040142A5 JP2013040142A5 (en) | 2014-09-04 |
| JP5997425B2 JP5997425B2 (en) | 2016-09-28 |
Family
ID=47888882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011178937A Active JP5997425B2 (en) | 2011-08-18 | 2011-08-18 | Ornithine-containing composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5997425B2 (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001510145A (en) * | 1997-07-14 | 2001-07-31 | エヌ・ヴイ・ヌートリシア | Nutritional composition containing methionine |
| WO2004052125A1 (en) * | 2002-12-06 | 2004-06-24 | Kyowa Hakko Kogyo Co., Ltd. | Beverage containing amino acid and method of diminishing bitterness of amino acid |
| WO2005023021A1 (en) * | 2003-09-02 | 2005-03-17 | Bbk Bio Corporation | Diet food |
| JP2006342148A (en) * | 2005-05-13 | 2006-12-21 | Kyowa Hakko Kogyo Co Ltd | Oral medicament for improvement in going to sleep or waking |
| JP2007055992A (en) * | 2004-11-02 | 2007-03-08 | Ajinomoto Co Inc | Medicament for perioperative patient |
| WO2007142286A1 (en) * | 2006-06-07 | 2007-12-13 | Kyowa Hakko Bio Co., Ltd. | Fatigue-reducing agent |
| JP2008073007A (en) * | 2006-09-25 | 2008-04-03 | Kyowa Hakko Kogyo Co Ltd | Vinegar acidity suppressing method |
| WO2008072725A1 (en) * | 2006-12-15 | 2008-06-19 | Kyowa Hakko Bio Co., Ltd. | Composition containing agaricus blazei murill |
| JP2008214232A (en) * | 2007-03-02 | 2008-09-18 | Kyowa Hakko Kogyo Co Ltd | Collagen synthesis promoter |
| JP2011120479A (en) * | 2009-12-08 | 2011-06-23 | Kirin Holdings Co Ltd | Basic amino acid-containing packaged beverage |
-
2011
- 2011-08-18 JP JP2011178937A patent/JP5997425B2/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001510145A (en) * | 1997-07-14 | 2001-07-31 | エヌ・ヴイ・ヌートリシア | Nutritional composition containing methionine |
| WO2004052125A1 (en) * | 2002-12-06 | 2004-06-24 | Kyowa Hakko Kogyo Co., Ltd. | Beverage containing amino acid and method of diminishing bitterness of amino acid |
| WO2005023021A1 (en) * | 2003-09-02 | 2005-03-17 | Bbk Bio Corporation | Diet food |
| JP2007055992A (en) * | 2004-11-02 | 2007-03-08 | Ajinomoto Co Inc | Medicament for perioperative patient |
| JP2006342148A (en) * | 2005-05-13 | 2006-12-21 | Kyowa Hakko Kogyo Co Ltd | Oral medicament for improvement in going to sleep or waking |
| WO2007142286A1 (en) * | 2006-06-07 | 2007-12-13 | Kyowa Hakko Bio Co., Ltd. | Fatigue-reducing agent |
| JP2008073007A (en) * | 2006-09-25 | 2008-04-03 | Kyowa Hakko Kogyo Co Ltd | Vinegar acidity suppressing method |
| WO2008072725A1 (en) * | 2006-12-15 | 2008-06-19 | Kyowa Hakko Bio Co., Ltd. | Composition containing agaricus blazei murill |
| JP2008214232A (en) * | 2007-03-02 | 2008-09-18 | Kyowa Hakko Kogyo Co Ltd | Collagen synthesis promoter |
| JP2011120479A (en) * | 2009-12-08 | 2011-06-23 | Kirin Holdings Co Ltd | Basic amino acid-containing packaged beverage |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5997425B2 (en) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5188181B2 (en) | Composition for suppressing increase in blood alcohol concentration | |
| JP5053535B2 (en) | Oral for improving sleep or waking up | |
| JP4931352B2 (en) | Iron supplement and its use | |
| JP5421769B2 (en) | Liquid nutrition composition containing sodium in high concentration and method for producing the same | |
| JP5224680B2 (en) | Anti-fatigue | |
| JP2008143811A (en) | Lipid metabolism promoting composition | |
| JP2012126683A (en) | Composition for sympathetic activation | |
| JP2008088101A (en) | Antifatigue agent | |
| JP2004262927A (en) | Serum cholesterol-reducing agent, food or drink, and method for producing the same | |
| JP5997425B2 (en) | Ornithine-containing composition | |
| JP2009013143A (en) | Sleep-improving composition | |
| WO2013062015A1 (en) | Sweet composition showing reduced bitterness of sweetener having bitter taste, method for reducing bitterness, and food, drink, drug or quasi drug having reduced bitterness | |
| JP2002255801A (en) | Composition for prophylaxis of hypertension | |
| JP4847732B2 (en) | Cold remedy | |
| JP2007031375A (en) | Oral agent for ameliorating skin quality | |
| JP2007031403A (en) | Lactic acid production inhibitor | |
| JP2021100421A (en) | Composition for improving liver function, and food composition for improving liver function | |
| JP5041780B2 (en) | Liver disorder improving composition | |
| JP2010195734A (en) | Phytic acid, carboxylic acid, and composition having fat absorption inhibitory action by synergistic effect of saccharides | |
| JP2010095474A (en) | Calcium absorption-promoting composition and calcium absorption-promoting food and drink | |
| US20060258746A1 (en) | Oral medicament for improvement in going to sleep or waking | |
| JP6391066B2 (en) | Ornithine-containing composition for improving body composition | |
| JP4645842B2 (en) | Royal jelly-containing beverage composition | |
| JP4645841B2 (en) | Royal jelly-containing beverage composition | |
| JP2009023948A (en) | Dopamine-inhibiting agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140716 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140716 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150828 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160318 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160510 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160513 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160707 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160802 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160826 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5997425 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |